Shire, Adherex terminate cancer deal

Shire (LSE:SHP; SHPGY) and Adherex (TSE:AHX) terminated their development deal for AHX's Exherin anti-adhesion system small molecule, which is in preclinical testing for cancer. AHX said that, given t...